Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2017

Jan 11, 2017

30198_dirs_2017-01-11_b1178d25-2ebe-4bb0-af3e-f288dc6ba732.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2017-01-09

Reporting Person: VALDES JORGE A (CTO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-01-09 Common Stock M 7000 $7.79 Acquired 79334 Direct
2017-01-09 Common Stock S 7000 $63.0232 Disposed 72334 Direct
2017-01-09 Common Stock M 417 $7.63 Acquired 72751 Direct
2017-01-09 Common Stock S 417 $63.4875 Disposed 72334 Direct
2017-01-09 Common Stock M 900 $3.19 Acquired 73234 Direct
2017-01-09 Common Stock S 900 $63.3118 Disposed 72334 Direct
2017-01-09 Common Stock M 2583 $7.63 Acquired 74917 Direct
2017-01-09 Common Stock S 2583 $62.8291 Disposed 72334 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-01-09 Incentive Stock Option (right to buy) $7.63 M 417 Disposed 2018-05-19 Common Stock (417) Direct
2017-01-09 Incentive Stock Option (right to buy) $7.79 M 7000 Disposed 2017-08-02 Common Stock (7000) Direct
2017-01-09 Non-Qualified Stock Option (right to buy) $7.63 M 2583 Disposed 2018-05-19 Common Stock (2583) Direct
2017-01-09 Non-Qualified Stock Option (right to buy) $ M 900 Disposed 2018-12-11 Common Stock (900) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 3499 Indirect

Footnotes

F1: On November 4, 2016 Mr. Valdes adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Valdes. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: This transaction was executed in multiple trades at prices ranging from $62.48 to $63.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3: Included in this number are 72,334 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 22,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 11,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017.

F4: This transaction was executed in multiple trades at prices ranging from $63.37 to $63.65. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F5: This transaction was executed in multiple trades at prices ranging from $63.17 to $63.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F6: This transaction was executed in multiple trades at prices ranging from $62.49 to $63.17. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F7: Shares are held by the Valdes-Lopez-Calleja Family Trust U/A/D 05/18/2011, with respect to which the reporting person is a trustee.

F8: Conversion or exercise price of derivative security is $3.19.